Quantum Clinical Trials — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$249,465	209
2024	Research	$574,008	21
2023	Research	$1,141,289	54
2022	Research	$1,015,648	52
2021	Research	$266,965	25

Breakdown

Who paid Research payments · program years 2021–2025

Endo Pharmaceuticals Inc. $1,128,538 44 payments
Mylan Inc. $817,496 41 payments
Urovant Sciences Inc $661,916 33 payments
Sumitomo Pharma America, Inc. $227,492 15 payments
AbbVie, Inc. $226,543 32 payments
Ipsen Innovation $169,936 182 payments
Indivior Inc. $15,453 14 payments

Studies the money was for Research payments · program years 2021–2025

An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products $1,128,538 44 payments
Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $817,496 41 payments
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $793,429 37 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $128,571 10 payments
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $89,200 18 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $86,164 109 payments
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $83,772 73 payments
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $48,234 8 payments
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (Oab) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $47,744 3 payments
A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $15,453 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.